Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cinqair

- PMLiVE

Leukaemia drug prices “unsustainable” say cancer experts

Study says patients may not be able to afford effective treatment

- PMLiVE

Lilly expects to submit five drugs for US approval in 2013

Hopes FDA submissions will help offset patent losses for Zyprexa and Cymbalta

- PMLiVE

FDA stung by damning fraudulent research report

Agency accused of leaving untested drugs on the market

Lilly ramps up social media use

Next phase of LillyPad blog expansion aims at journalists

- PMLiVE

FDA bars generic version of Purdue’s painkiller OxyContin

New abuse-deterrent formulation means original version no longer has positive benefit-to-risk profile

- PMLiVE

Lilly “plans to axe a third of US sales reps”

Cuts come ahead of key patent expiries for Cymbalta and Evista

- PMLiVE

FDA approves return of morning sickness drug for pregnant women

Regulator confirms safety of Diclegis – formerly known as Bendectin

Bayer symbol

Bayer’s riociguat fast-tracked by FDA

Could provide oral option in pulmonary arterial hypertension market

- PMLiVE

Lilly to invest extra $180m in US insulin manufacturing

Response to growing demand for insulin pens for people with diabetes

- PMLiVE

Boehringer – Lilly file empagliflozin for European approval

EMA begins review of the companies' new type 2 diabetes drug

- PMLiVE

FDA delays GlaxoSmithKline’s pandemic flu vaccine

More time needed due to "administrative" issue

FDA says final mobile app guidance just weeks away

And tells Congress only a fraction of mobile apps will need regulating

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links